These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37282836)

  • 1. Recent advances in stimuli-responsive polymeric carriers for controllable CRISPR/Cas9 gene editing system delivery.
    Ma P; Wang Q; Luo X; Mao L; Wang Z; Ye E; Loh XJ; Li Z; Wu YL
    Biomater Sci; 2023 Jul; 11(15):5078-5094. PubMed ID: 37282836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-viral delivery of genome-editing nucleases for gene therapy.
    Wang M; Glass ZA; Xu Q
    Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
    He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
    Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
    Li L; Hu S; Chen X
    Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
    Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.
    Fang T; Cao X; Ibnat M; Chen G
    J Nanobiotechnology; 2022 Aug; 20(1):354. PubMed ID: 35918694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.
    Okoli A; Okeke MI; Tryland M; Moens U
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29361752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
    Zhang S; Shen J; Li D; Cheng Y
    Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for
    Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ
    ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
    Wan T; Ping Y
    Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.